| Literature DB >> 22792174 |
Joanne M Kingsbury1, Joseph Heitman, Sheldon R Pinnell.
Abstract
Superficial mycoses caused by dermatophyte fungi are among the most common infections worldwide, yet treatment is restricted by limited effective drugs available, drug toxicity, and emergence of drug resistance. The stilbene fluorescent brightener calcofluor white (CFW) inhibits fungi by binding chitin in the cell wall, disrupting cell wall integrity, and thus entails a different mechanism of inhibition than currently available antifungal drugs. To identify novel therapeutic options for the treatment of skin infections, we compared the sensitivity of representative strains of the dermatophyte Trichophyton rubrum and Candida albicans to CFW and a panel of fluorescent brighteners and phytoalexin compounds. We identified the structurally related stilbene fluorescent brighteners 71, 85, 113 and 134 as fungicidal to both T. rubrum and C. albicans to a similar degree as CFW, and the stilbene phytoalexins pinosylvan monomethyl ether and pterostilbene inhibited to a lesser degree, allowing us to develop a structure-activity relationship for fungal inhibition. Given the abilities of CFW to absorb UV(365 nm) and bind specifically to fungal cell walls, we tested whether CFW combined with UV(365 nm) irradiation would be synergistic to fungi and provide a novel photodynamic treatment option. However, while both treatments individually were cytocidal, UV(365 nm) irradiation reduced sensitivity to CFW, which we attribute to CFW photoinactivation. We also tested combination treatments of CFW with other fungal inhibitors and identified synergistic interactions between CFW and some ergosterol biosynthesis inhibitors in C. albicans. Therefore, our studies identify novel fungal inhibitors and drug interactions, offering promise for combination topical treatment regimes for superficial mycoses.Entities:
Mesh:
Substances:
Year: 2012 PMID: 22792174 PMCID: PMC3391284 DOI: 10.1371/journal.pone.0039405
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Figure 1Structures of representative stilbene and non-stilbene fluorescent brighteners and stilbene phytoalexin compounds.
Residues (R) at which related products differ from the representative compound are displayed. A. CFW. B. Fluorescent brightener 351. C. Brilliant yellow. D. Fluorescent brightener ER-III. E. 4,4′-diamino-2–2′-stilbenedisulfonic acid. F. Fluorescent brightener 135. G. Pinosylvan monomethyl ether.
Inhibition of T. rubrum ATCC MYA-4438 and C. albicans SC5314 by fluorescent brightener and stilbene compounds.
| Compound |
|
|
|
| Related structure | Differing residues |
|
| ||||||
| CFW | 2.87 | 5.73 | 11.46–22.92 | 22.92–45.85 | A | |
| FB 85 | 2.73 | 5.56 | 10.91 | 21.82 | A | R1 |
| FB 113 | 3.00 | 6.01 | 12.01 | 24.02 | A | R1 |
| FB 71 | 2.89 | 5.78 | 11.56 | >46.25 | A | R1 |
| FB 134 | 5.09 | 10.18 | 20.37 | 162.95 | A | R1 |
| FB 220 | 36.41 | 72.81 | 582.52 | >1165.03 | A | R2 |
| FB 351 (Uvitex 2B) | 28.13 | 56.26 | 28.13 | >225.03 | B | |
| Brilliant yellow | 7.81 | >124.91 | >124.91 | >124.91 | C | |
| FB 210 | 112.90 | >225.80 | >225.80 | >225.80 | A | R1, R2 |
| FB ER-II | >66.48 | >66.48 | >66.48 | >66.48 | D | R3, R4 |
| FB ER-III | >66.48 | >66.48 | >66.48 | >66.48 | D | |
| 4,4′-diamino-2–2′-stilbenedisulfonic acid | >74.08 | >74.08 | >74.08 | >74.08 | E | |
| 4,4′-diisothiocyanatostilbene-2,2′-disulfonic acid | >99.70 | >99.70 | >99.70 | >99.70 | E | R5 |
|
| ||||||
| FB 135 | >14.52 | >14.52 | >14.52 | >14.52 | F | |
|
| ||||||
| Pinosylvin mono methyl ether | 5.66 | 11.31 | 22.63 | 45.26 | G | |
| Pterostilbene | 6.40 | 25.60 | 25.60 | 25.60 | G | R6, R8 |
| Pinosylvin | 21.22 | 42.45 | ≥42.45 | >42.45 | G | R7 |
| Resveratrol | >45.65 | >45.65 | >45.65 | >45.65 | G | R7, R8 |
| Astringin | >81.20 | >81.20 | >81.20 | >81.20 | G | R7, R8, R9 |
| Rhapontin | >84.08 | >84.08 | >84.08 | >84.08 | G | R7, R8, R9 |
See Fig. 1 for structures and residues.
Combination treatments with CFW and UV365 nm irradiation.
| UV treatment (J/cm2) |
|
|
|
|
| 0 | 2.87 | 2.87 | 11.46 | 45.85 |
| 18.7 | 45.85 | 91.70 | 183.40 | >183.40 |
| 37.4 | 22.92 | 91.70 | 2.87 | 22.92 |
| 56.2 | 0 | 91.70 | 0.36 | 1.43 |
80% growth inhibition for UV treatment alone was 56.2 J/cm2 for T. rubrum and 149.6 J/cm2 for C. albicans. 99% and 95% fungicidal UV treatment alone was 74.8 J/cm2 for T. rubrum and 149.6 J/cm2 for C. albicans, respectively.
Tabele 3. T. rubrum ATCC MYA-4438 and C. albicans SC5314 combination drug treatments with CFW.
| Drug |
|
| ||||
| Individual MIC80(µg/ml)(CFW/drug) | Combined MIC80(µg/ml)(CFW/drug) | FIC | Individual MIC80(µg/ml)(CFW | Combined MIC80(µg/ml)(CFW/drug) | FIC | |
|
| ||||||
| Clotrimazole | 2.87/0.034 | 1.43/0.017 | 1 | 11.46/0.022 | 1.43/0.011 | 0.63 |
| Itraconazole | 2.87/0.110 | 1.43/0.028 | 0.75 | 11.46/0.022 | 5.73/0.003 | 0.63 |
| Miconazole | 2.87/0.150 | 2.87/0.150 | 2 | 22.92/2.40 | 5.73/0.019 | 0.26 |
| Thioconazole | 2.87/0.060 | 2.87/0.060 | 2 | 5.73/0.006 | 0.72/0.003 | 0.63 |
| Voriconazole | 2.87/0.014 | 2.87/0.014 | 2 | 11.46/0.011 | 5.73/0.003 | 0.75 |
|
| ||||||
| Butenafine HCl | 2.87/1.77 | 1.43/0.88 | 1 | 22.92/>17.70 | 22.92/>17.70 | NA |
| Terbinafine HCl | 2.87/4.10 | 1.43/2.05 | 1 | 22.92/>131.16 | 11.46/1.02 | NA |
|
| ||||||
| Griseofulvin | 2.87/0.55 | 1.43/0.28 | 1 | 22.92/>17.74 | 22.92/>17.74 | NA |
| Manumycin A | 2.87/10.32 | 2.87/10.32 | 2 | 22.92/22.03 | 5.73/11.01 | 0.75 |
| Fenpropimorph | 2.87/0.237 | 2.87/0.237 | 2 | 22.92/15.17 | 2.87/0.030 | 0.13 |
| Rapamycin | 2.87/>45.71 | 0.72/1.43 | NA | 11.46/0.09 | 5.73/0.023 | 0.75 |
| Nikkomycin Z | 2.87/>49.54 | 2.87/>49.54 | NA | 11.46/>24.77 | >45.85/6.19 | NA |
Some experiment-to-experiment differences in CFW MIC80 s for C. albicans were observed, such as for experiments where the MIC80 s were read after 24 h instead of 48 h.
Not applicable. When the MIC80 for any drug was higher than the highest concentration tested, the FIC could not be determined.
Figure 2Disc diffusion assays showing enhanced C. albicans inhibition when treated with CFW and ergosterol biosynthesis inhibitors.
Starting at the bottom right disc and moving clockwise, the amounts of each drug added per disc included 14.11, 3.52, 1.41 and 0 ng of itraconazole, 8.32, 2.08, 0.83, and 0 ng of miconazole, and 6.07, 1.52, 0.61, and 0 ng of fenpropimorph. Drugs were diluted in DMSO, and DMSO comprised the no-drug control.